Delaware
|
94-3023969
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
Incorporation)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Name
|
|
Title
|
|
Target
Bonus
|
Maximum
Bonus
|
Ratio
of 2011
Corporate
Goals/
2011
Individual
Goals
|
John
P.
McLaughlin
|
|
President and
Chief
Executive
Officer
|
|
70%
|
105%
|
100%/0%
|
Christine
R.
Larson
|
|
Vice
President and Chief
Financial
Officer
|
|
50%
|
75%
|
75%/25%
|
Christopher
Stone
|
Vice
President, General
Counsel
and Secretary
|
50%
|
75%
|
75%/25%
|
2011
Corporate Goal
|
|
Weight
|
Optimize
Value of Patent Estate
|
|
65%
|
Implement
Corporate Strategy & Business Development
|
|
20%
|
Manage
Risk and Maintain Capital Structure within Guidelines
|
|
10%
|
Enhance
Investor Relations
|
|
5%
|
Total
|
|
100%
|
Exhibit
No.
|
Description
|
|
10.1
|
PDL
BioPharma, Inc. 2011 Annual Bonus
Plan
|
PDL
BIOPHARMA, INC.
(Company)
|
|||
|
By:
|
/s/ Christopher Stone | |
Christopher Stone | |||
Vice President, General Counsel and Secretary | |||
Exhibit
No.
|
Description
|
|
10.1
|
PDL
BioPharma, Inc. 2011 Annual Bonus
Plan
|